Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.

von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, Matee M, Bakari M, Tvaroha S, Adams LV, Horsburgh CR, Pallangyo K; DarDar Study Group..

AIDS. 2010 Mar 13;24(5):675-85. doi: 10.1097/QAD.0b013e3283350f1b.

PMID:
20118767
2.

Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial.

Vuola JM, Ristola MA, Cole B, Järviluoma A, Tvaroha S, Rönkkö T, Rautio O, Arbeit RD, von Reyn CF.

AIDS. 2003 Nov 7;17(16):2351-5.

PMID:
14571187
3.

Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial.

Matee M, Lahey T, Vuola JM, Mtei L, Cole BF, Bakari M, Arbeit RD, Horsburgh CR, Pallangyo K, von Reyn CF.

J Infect Dis. 2007 Jan 1;195(1):118-23.

4.

Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis.

Waddell RD, Chintu C, Lein AD, Zumla A, Karagas MR, Baboo KS, Habbema JD, Tosteson AN, Morin P, Tvaroha S, Arbeit RD, Mwinga A, von Reyn CF.

Clin Infect Dis. 2000 Jun;30 Suppl 3:S309-15.

PMID:
10875806
5.

Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality.

von Reyn CF, Kimambo S, Mtei L, Arbeit RD, Maro I, Bakari M, Matee M, Lahey T, Adams LV, Black W, Mackenzie T, Lyimo J, Tvaroha S, Waddell R, Kreiswirth B, Horsburgh CR, Pallangyo K.

Int J Tuberc Lung Dis. 2011 Aug;15(8):1087-92. doi: 10.5588/ijtld.10.0517.

PMID:
21740673
6.

Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis.

Haile M, Schröder U, Hamasur B, Pawlowski A, Jaxmar T, Källenius G, Svenson SB.

Vaccine. 2004 Mar 29;22(11-12):1498-508.

PMID:
15063575
7.

Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.

Lahey T, Arbeit RD, Bakari M, Horsburgh CR, Matee M, Waddell R, Mtei L, Vuola JM, Pallangyo K, von Reyn CF.

Vaccine. 2010 Nov 10;28(48):7652-8. doi: 10.1016/j.vaccine.2010.09.041.

9.

The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.

Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, Beyers N.

Vaccine. 2007 Jan 2;25(1):14-8.

PMID:
16959383
10.

The immune response to BCG vaccination of newborns.

Hanekom WA.

Ann N Y Acad Sci. 2005 Dec;1062:69-78. Review.

PMID:
16461790
11.

Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects.

Wallace MR, Brandt CJ, Earhart KC, Kuter BJ, Grosso AD, Lakkis H, Tasker SA.

Clin Infect Dis. 2004 Oct 15;39(8):1207-13.

PMID:
15486846
12.

Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child.

Kroidl A, Huck K, Weinspach S, Gudowius S, Mackenzie CR, Oette M, Häussinger D, Niehues T.

Scand J Infect Dis. 2006;38(8):716-8.

PMID:
16857624
13.

Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.

Lahey T, Sheth S, Matee M, Arbeit R, Horsburgh CR, Mtei L, Mackenzie T, Bakari M, Vuola JM, Pallangyo K, von Reyn CF.

J Infect Dis. 2010 Oct 15;202(8):1265-72. doi: 10.1086/656332.

14.

A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination.

Hoft DF, Kemp EB, Marinaro M, Cruz O, Kiyono H, McGhee JR, Belisle JT, Milligan TW, Miller JP, Belshe RB.

J Lab Clin Med. 1999 Sep;134(3):244-52.

PMID:
10482309
15.

High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania.

Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, Cole BF, Vuola JM, Tvaroha S, Kreiswirth B, Pallangyo K, von Reyn CF.

Clin Infect Dis. 2005 May 15;40(10):1500-7.

PMID:
15844073
16.

Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children.

Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, Gie RP, Marais BJ, van Helden P, Warren RM.

Clin Infect Dis. 2003 Nov 1;37(9):1226-33. Erratum in: Clin Infect Dis. 2003 Dec 15;37(12):1727.

PMID:
14557968
17.

New vaccines for the prevention of tuberculosis.

von Reyn CF, Vuola JM.

Clin Infect Dis. 2002 Aug 15;35(4):465-74.

PMID:
12145732
18.

Adverse effects of bacille Calmette-Guerin vaccination in HIV-positive infants.

Hussey G, Hawkridge T, Eley B, Nuttall J, Kibel M, Geiter L, Barker L, Behr M, Demers AM.

Clin Infect Dis. 2004 May 1;38(9):1333-4; author reply 1334-5. No abstract available.

PMID:
15127353
19.

Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette-Guérin from infection with Mycobacterium tuberculosis.

Roche PW, Triccas JA, Avery DT, Fifis T, Billman-Jacobe H, Britton WJ.

J Infect Dis. 1994 Nov;170(5):1326-30.

PMID:
7963739
Items per page

Supplemental Content

Support Center